Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxercalciferol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 9/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.80 |
| ▸ | PGR | P06401 | 1/20 | 0.80 |
| ▸ | HTR1A | P08908 | 1/20 | 0.80 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.80 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | AR | P10275 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | USP2 | O75604 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | ESR1 | P03372 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxercalciferol SCHEMBL7152665 | 1.00 | VDR (1.00) | VDRADRA1AADORA3SLC6A2NR1I2 | |
| Doxercalciferol SCHEMBL322422 | 1.00 | VDR (1.00) | VDRADRA1AADORA3SLC6A2NR1I2 | |
| Doxercalciferol SCHEMBL10337669 | 1.00 | VDR (1.00) | VDRADRA1AADORA3SLC6A2NR1I2 | |
| Doxercalciferol SCHEMBL15262963 | 1.00 | VDR (1.00) | VDRADRA1AADORA3SLC6A2NR1I2 | |
| Doxercalciferol SCHEMBL10018929 | 1.00 | VDR (1.00) | VDRADRA1AADORA3SLC6A2NR1I2 | |
| Doxercalciferol SCHEMBL3999503 | 1.00 | VDR (1.00) | VDRADRA1AADORA3SLC6A2NR1I2 | |
| Doxercalciferol SCHEMBL24066841 | 1.00 | VDR (1.00) | VDRADRA1AADORA3SLC6A2NR1I2 | |
| Doxercalciferol SCHEMBL9051060 | 1.00 | VDR (1.00) | VDRADRA1AADORA3SLC6A2NR1I2 | |
| Doxercalciferol SCHEMBL21433257 | 1.00 | VDR (1.00) | VDRADRA1AADORA3SLC6A2NR1I2 | |
| Doxercalciferol SCHEMBL9980508 | 1.00 | VDR (1.00) | VDRADRA1AADORA3SLC6A2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114755323-A | Method and kit for detecting content of fat-soluble vitamins in dried blood paper | 北京和合医学诊断技术股份有限公司 | 2022-07-15 | — | — | CN | claimed |
| CN-114460314-B | Multivitamin D analogue detection kit and detection method | 普迈德（北京）科技有限公司 | 2022-06-24 | — | — | CN | claimed |
| CN-114460314-A | Detection kit and detection method for multivitamin D analogues | 普迈德（北京）科技有限公司 | 2022-05-10 | — | — | CN | claimed |
| CN-113655132-A | Method and kit for detecting content of 25 hydroxy vitamin D in human serum | 艾可泰科生物科技(江苏)有限公司 | 2021-11-16 | — | — | CN | claimed |
| CN-113189237-A | Analysis method for evaluating matrix effect of endogenous serum compounds | 重庆黄嘉同怡科技有限公司 | 2021-07-30 | — | — | CN | claimed |
| EP-2633325-B1 | LC-MS SEPARATION AND DETECTION OF VITAMIN D METABOLITES | COHESIVE TECH INC (US) | 2016-12-28 | — | — | EP | claimed |
| EP-2948474-A1 | METHOD AND KIT FOR DETECTING 1,25-DIHYDROXYVITAMIN D AND RELATED ANTIBODIES | DiaSorin S.p.A. (IT) | 2015-12-02 | — | — | EP | claimed |
| US-9063159-B2 | LC-MS separation and detection of vitamin D metabolites | COHESIVE TECHNOLOGIES INC. (US) | 2015-06-23 | — | — | US | claimed |
| WO-2014114780-A1 | METHOD AND KIT FOR DETECTING 1,25-DIHYDROXYVITAMIN D AND RELATED ANTIBODIES | DIASORIN S.P.A. (IT) | 2014-07-31 | — | — | WO | claimed |
| JP-2006519854-A | — | — | 2006-08-31 | — | — | JP | claimed |
| WO-2005102355-A1 | METHODS OF TREATING VARIOUS VITAMIN D METABOLISM CONDITIONS WITH 1α-HYDROXYVITAMIN D2 | GENZYME CORPORATION (US) | 2005-11-03 | — | — | WO | claimed |
| WO-2004080467-A2 | METHOD OF TREATING AND PREVENTING HYPERPARATHYROIDISM WITH VITAMIN D2 OR D4 COMPOUNDS | BONE CARE INTERNATIONAL, INC. (US) | 2004-09-23 | — | — | WO | claimed |
| US-20030207847-A1 | Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis | DELUCA HECTOR F (US) | 2003-11-06 | — | — | US | claimed |
| US-20030022873-A1 | Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis | DELUCA HECTOR F (US) | 2003-01-30 | — | — | US | claimed |
| EP-1196174-A1 | DIETARY CALCIUM AS A SUPPLEMENT TO VITAMIN D COMPOUND TREATMENT OF MULTIPLE SCLEROSIS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2002-04-17 | — | — | EP | claimed |
| US-20020016313-A1 | DIETARY CALCIUM AS A SUPPLEMENT TO VITAMIN D COMPOUND TREATMENT OF MULTIPLE SCLEROSIS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2002-02-07 | — | — | US | claimed |
| WO-2001003704-A1 | DIETARY CALCIUM AS A SUPPLEMENT TO VITAMIN D COMPOUND TREATMENT OF MULTIPLE SCLEROSIS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2001-01-18 | — | — | WO | claimed |
| EP-0398715-B1 | Method of exterminating rodents and other vertebrate pests | WISCONSIN ALUMNI RES FOUND (US) | 1995-04-19 | — | — | EP | claimed |
| EP-0112332-B1 | VITAMIN D GLYCOSIDES | THE GENERAL HOSPITAL CORPORATION (US) | 1993-06-16 | — | — | EP | claimed |
| EP-0398715-A2 | Method of exterminating rodents and other vertebrate pests | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1990-11-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207847-A1 | Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis | VDR, ORAI1, CYP24A1 | VDR 1/4885ADRA1A 2898/4885ADORA3 605/4885 |
| US-20020016313-A1 | DIETARY CALCIUM AS A SUPPLEMENT TO VITAMIN D COMPOUND TREATMENT OF MULTIPLE SCLEROSIS | VDR, ORAI1, CYP24A1 | VDR 1/4885ADRA1A 2898/4885ADORA3 605/4885 |
| US-20030022873-A1 | Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis | VDR, ORAI1, CYP24A1 | VDR 1/4885ADRA1A 2898/4885ADORA3 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.